Most Read

Molnupiravir is an orally administered form of a potent ribonucleoside analogue that blocks the SARS-CoV-2 replication. It is planned to be sold under the trademark Lagevrio in the

This brings the company’s total Series A funding raised to $107m. The financing was led by Third Rock Ventures and saw participation from Smilegate Investment, Schroders Capital, Alexandria

The long-acting injectable is indicated for use in adults and adolescents who are at risk of sexually acquiring HIV and test negative for HIV-1 before initiation. The regulatory

Developed using Novavax’ recombinant nanoparticle technology, the vaccine also known as NVX-CoV2373 is a protein-based Covid-19 vaccine candidate which is engineered from the genetic sequence of the initial

A fully human monoclonal antibody, Saphnelo targets subunit 1 of the type one interferon (type 1 IFN) receptor, blocking the type 1 IFN’s activity. It has been recommended

Alpine Immune Sciences and Horizon Therapeutics have signed an exclusive licence and collaboration agreement to develop protein-based therapies to treat autoimmune and inflammatory diseases. As agreed, Horizon will

The funding round had seen participation from Innovent Biologics, Cenova, Laurion Capital, and Sage Partners. The firm has raised a total of $100m from private financings since it

The research collaboration will explore the treatment potential of exosomes and other extracellular vesicles generated by neural stem cells drawn from AgeX pluripotent stem cells. The aim of

Besides the $100m upfront payment, Zealand will receive $50m in exchange for an additional note with terms and conditions in line with the secured note. This is available